The 2nd Target Actionability Review (TAR) on CDK4/6 as drug targets in pediatric cancers has been finalized by authors of the ITCCP4 consortium.
For neuroblastoma, Ewing sarcoma, osteosarcoma and RT/ATRT cancers there is good preclinical evidence that targetting CDK4/6 with small molecules is especially effective in preclinical models in combination with other drugs, such as other kinase inhibitors or chemotherapy.
